

IMCOR Pharmaceutical Co. Announces the Commencement of a Phase 2 Repeat Dosing Clinical Trial

Tuesday December 7, 8:02 am ET

SAN DIEGO--(BUSINESS WIRE)--Dec. 7, 2004--IMCOR Pharmaceutical Co. (OTC:[ICPH - News](#)), announced today that it has commenced a Phase 2 clinical study designed to investigate alternative methods of administration for Imagent® (perflexane lipid microsphere), including repeat dosing and infusion. This study is part of a series of clinical studies to establish the safety and efficacy of Imagent when administered at higher doses. This study will assist in providing additional information regarding the use of Imagent for new indications such as myocardial perfusion imaging and radiology applications.

"Our clinical plan for Imagent calls for a very organized approach to provide the most versatile ultrasound contrast agent for all physicians. There are many opportunities to improve the diagnosis of disease with the use of Imagent to enable more effective and timely treatment. We plan to take a targeted approach to achieving important new indications for our approved agent. The first of these will be myocardial perfusion," said Taffy J. Williams, Ph.D., President and Chief Executive Officer of IMCOR.

One approach to be pursued is myocardial perfusion imaging using the phasic changes imaging method. A preliminary study using this method showed encouraging results for the detection of coronary artery disease without the need to stress the heart of the patient, which is currently required with the existing imaging procedures. A multi-center clinical trial is being planned to further investigate these positive findings.

IMCOR Pharmaceutical Co. is a specialty pharmaceutical company developing and marketing a platform of innovative imaging products including its current ultrasound contrast agent, Imagent and PH-50, an investigational iodinated, nanoparticulate formulation under evaluation as a subcutaneous or intravenous agent for both cardiovascular imaging and lymphography. For more information on IMCOR Pharmaceutical Co., visit www.imcorpharma.com.

Statements in this release that are not strictly historical are "forward-looking" statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks that may cause IMCOR's actual results in the future to differ materially from expected results. These risks and uncertainties include the ability of the company to: obtain necessary financing to support its development and commercialization programs, maintain and defend intellectual property protection for its proprietary products, avoid infringing intellectual property rights of third parties, successfully market its approved product, develop products and indications and obtain regulatory approval for their use and manufacture or obtain supplies of drug product. These and other risks are described and qualified in their entirety by cautionary language and risk factors set forth in IMCOR's filings from time to time with the Securities and Exchange Commission. IMCOR undertakes no obligation to publicly update any forward-looking statement.

Contact:

IMCOR Pharmaceutical Co.
Taffy J. Williams, 858-410-5613
info@imagentcontrast.com

Source: IMCOR Pharmaceutical Co.